Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C34H41FN4O4S2 |
| Molecular Weight | 652.842 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CSCC[C@H](NC(=O)C1=C(CCC2=CC=C(F)C=C2)C=CC(NC[C@@H]3C[C@@H](CN3)SC(=O)C4=CN=CC=C4)=C1)C(=O)OC(C)C
InChI
InChIKey=HKGUHEGKBLYKHY-QMOZSOIISA-N
InChI=1S/C34H41FN4O4S2/c1-22(2)43-33(41)31(14-16-44-3)39-32(40)30-18-27(13-10-24(30)9-6-23-7-11-26(35)12-8-23)37-20-28-17-29(21-38-28)45-34(42)25-5-4-15-36-19-25/h4-5,7-8,10-13,15,18-19,22,28-29,31,37-38H,6,9,14,16-17,20-21H2,1-3H3,(H,39,40)/t28-,29-,31-/m0/s1
| Molecular Formula | C34H41FN4O4S2 |
| Molecular Weight | 652.842 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 18:33:19 UTC 2023
by
admin
on
Sat Dec 16 18:33:19 UTC 2023
|
| Record UNII |
F99W9H5WUE
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
F99W9H5WUE
Created by
admin on Sat Dec 16 18:33:19 UTC 2023 , Edited by admin on Sat Dec 16 18:33:19 UTC 2023
|
PRIMARY | |||
|
AZD-3409
Created by
admin on Sat Dec 16 18:33:19 UTC 2023 , Edited by admin on Sat Dec 16 18:33:19 UTC 2023
|
PRIMARY | AZD3409 is a farnesyl-transferase inhibitor (FAR) indicated for the treatment of solid tumors. Phase I trials were initiated January 2003, and were ongoing as of February 2004. As of February 2007 the development of AZD3409 had been discontinued.AZD3409 is a novel, oral, antitumor agent that acts as a prenyl transferase inhibitor. It has potentially broad antitumor activity both as monotherapy and in combination with other anticancer treatments. AZD3409 is a double pro-drugits metabolism involves conversion to a thiol-ester intermediate, then, intracellularly, to a thiol-acid active species. Phase I trials were initiated January 2003, and were ongoing as of February 2004. Recent studies have shown that AZD3409 is a potent inhibitor of both prostate epithelial cell proliferation and cellular invasion, without an associated bone marrow cellular toxicity.In preclinical studies, AZD3409 achieves up to 90% inhibition of FTase in tumors at well tolerated doses. In enzyme studies AZD3409 is also known to inhibit GGTase-1. | ||
|
11377266
Created by
admin on Sat Dec 16 18:33:19 UTC 2023 , Edited by admin on Sat Dec 16 18:33:19 UTC 2023
|
PRIMARY | |||
|
345915-10-8
Created by
admin on Sat Dec 16 18:33:19 UTC 2023 , Edited by admin on Sat Dec 16 18:33:19 UTC 2023
|
PRIMARY | |||
|
AZD-3409
Created by
admin on Sat Dec 16 18:33:19 UTC 2023 , Edited by admin on Sat Dec 16 18:33:19 UTC 2023
|
PRIMARY | Description: AZD-3409 is a potent prenyl transferase inhibitor. AZD-3409 showed higher potency than lonafarnib. The mean IC(50) for cytotoxicity of AZD3409 was 510 in MEF cells, 10,600 in A549 cells and 6,170 in MCF7 cells, respectively. In these cells, the IC(50) for FTase activity of AZD3409 ranged from 3.0 to 14.2 nM and of lonafarnib from 0.26 to 31.3 nM. AZD3409 inhibits farnesylation to a higher extent than geranylgeranylation. Both inhibition of farnesylation and geranylgeranylation could not be correlated to the antiproliferative activity of the drug. AZD3409 might be active in gefitinib-resistant breast carcinoma. (Last update: 7/9/2015). |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLITE -> PARENT |
Major circulating metabolite in plasma
PLASMA
|
||
|
METABOLITE ACTIVE -> PRODRUG |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Class: Antineoplastic, Antiviral, Small molecule; Mechanism of Action: Farnesyltranstransferase inhibitor; Highest Development Phase: Discontinued for Hepatitis D Solid tumours; Most Recent Event: 22 Dec 2015 Discontinued - Phase-I for Hepatitis D in USA (PO).The mean IC(50) for cytotoxicity of AZD3409 and lonafarnib was 510 and 15,200 nM in MEF cells, 10,600 and 2,740 nM in A549 cells and 6,170 and 9,490 nM in MCF7 cells, respectively. In these cells, the IC(50) for FTase activity of AZD3409 ranged from 3.0 to 14.2 NM.
|